What is Zacks Research's Forecast for TMO Q2 Earnings?

Thermo Fisher Scientific Inc. (NYSE:TMO - Free Report) - Zacks Research lifted their Q2 2025 earnings per share estimates for shares of Thermo Fisher Scientific in a report issued on Wednesday, July 9th. Zacks Research analyst R. Department now anticipates that the medical research company will post earnings per share of $5.20 for the quarter, up from their previous forecast of $5.19. The consensus estimate for Thermo Fisher Scientific's current full-year earnings is $23.28 per share. Zacks Research also issued estimates for Thermo Fisher Scientific's Q2 2027 earnings at $7.08 EPS.

TMO has been the subject of several other reports. Barclays decreased their price target on shares of Thermo Fisher Scientific from $475.00 to $450.00 and set an "equal weight" rating for the company in a research report on Tuesday, June 24th. Wall Street Zen raised shares of Thermo Fisher Scientific from a "hold" rating to a "buy" rating in a report on Wednesday, May 21st. UBS Group cut Thermo Fisher Scientific from a "buy" rating to a "neutral" rating and lowered their price objective for the stock from $500.00 to $460.00 in a research report on Tuesday, July 8th. Evercore ISI reduced their target price on Thermo Fisher Scientific from $500.00 to $480.00 and set an "outperform" rating on the stock in a research report on Tuesday, July 8th. Finally, Scotiabank upgraded shares of Thermo Fisher Scientific from a "sector perform" rating to a "sector outperform" rating and set a $590.00 target price for the company in a research note on Friday. Four investment analysts have rated the stock with a hold rating and seventeen have issued a buy rating to the company's stock. According to MarketBeat.com, the company presently has an average rating of "Moderate Buy" and a consensus price target of $600.30.

Thermo Fisher Scientific Stock Down 2.2%

Thermo Fisher Scientific stock traded down $9.42 during mid-day trading on Friday, reaching $425.44. 2,819,178 shares of the company were exchanged, compared to its average volume of 2,002,908. Thermo Fisher Scientific has a 12-month low of $385.46 and a 12-month high of $627.88. The business has a fifty day moving average of $409.39 and a 200 day moving average of $475.87. The firm has a market cap of $160.60 billion, a P/E ratio of 24.95, a PEG ratio of 2.31 and a beta of 0.77. The company has a debt-to-equity ratio of 0.64, a quick ratio of 1.38 and a current ratio of 1.77.

Thermo Fisher Scientific (NYSE:TMO - Get Free Report) last released its quarterly earnings data on Wednesday, April 23rd. The medical research company reported $5.15 earnings per share for the quarter, beating the consensus estimate of $5.10 by $0.05. The firm had revenue of $10.36 billion during the quarter, compared to the consensus estimate of $10.23 billion. Thermo Fisher Scientific had a return on equity of 17.15% and a net margin of 15.19%. The firm's quarterly revenue was up .2% on a year-over-year basis. During the same period in the previous year, the company posted $5.11 earnings per share.

Institutional Investors Weigh In On Thermo Fisher Scientific

A number of hedge funds and other institutional investors have recently made changes to their positions in TMO. Cypress Advisory Group LLC bought a new stake in shares of Thermo Fisher Scientific during the 4th quarter worth $253,000. Intact Investment Management Inc. boosted its position in Thermo Fisher Scientific by 34.0% during the fourth quarter. Intact Investment Management Inc. now owns 2,600 shares of the medical research company's stock valued at $1,353,000 after purchasing an additional 660 shares during the last quarter. GAMMA Investing LLC boosted its position in Thermo Fisher Scientific by 22.0% during the first quarter. GAMMA Investing LLC now owns 4,862 shares of the medical research company's stock valued at $2,419,000 after purchasing an additional 877 shares during the last quarter. Deutsche Bank AG boosted its position in Thermo Fisher Scientific by 9.5% during the fourth quarter. Deutsche Bank AG now owns 1,321,633 shares of the medical research company's stock valued at $687,553,000 after purchasing an additional 114,277 shares during the last quarter. Finally, Hancock Whitney Corp raised its holdings in Thermo Fisher Scientific by 0.6% during the fourth quarter. Hancock Whitney Corp now owns 5,386 shares of the medical research company's stock valued at $2,802,000 after buying an additional 30 shares in the last quarter. Hedge funds and other institutional investors own 89.23% of the company's stock.

Insider Activity

In related news, EVP Gianluca Pettiti sold 300 shares of the firm's stock in a transaction that occurred on Monday, April 28th. The stock was sold at an average price of $429.93, for a total value of $128,979.00. Following the completion of the transaction, the executive vice president directly owned 23,167 shares of the company's stock, valued at $9,960,188.31. This trade represents a 1.28% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Company insiders own 0.33% of the company's stock.

Thermo Fisher Scientific Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Wednesday, October 15th. Shareholders of record on Monday, September 15th will be given a dividend of $0.43 per share. The ex-dividend date of this dividend is Monday, September 15th. This represents a $1.72 dividend on an annualized basis and a yield of 0.40%. Thermo Fisher Scientific's payout ratio is 10.09%.

Thermo Fisher Scientific Company Profile

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.